Company attributes
Other attributes
Revance Therapeutics is a publicly held biotechnology company based in Newark, California. It specializes in developing neuromodulators for the treatment of asthetic and therapeutic conditions. Revance uses a proprietary stabilizing excipient peptide technology to create differentiated therapies.
The company's lead product candidate, RT002 (DaxibotulinumtoxinA) for injection, is in clinical development for a broad range of aesthetic and therapeutic indications, including:
The skin that sits between the eyebrows and above the nose. Face wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors. Late stage clinical studies have produced positive results, with RT002 poised to progress to commercialization. Revance has also entered into an agreement with Fosun Pharmaceuticals for the exclusive rights to develop and commercialize RT002 in Mainland China, Hong Kong, and Macau.
An extremely painful, chronic neurological movement disorder where the neck and shoulder muscles contract involuntarily and contort, causing the head to twist or turn to the left, right, upwards, and/or downwards. RT002 has completed Phase 2 clinical trials for this condition.
A subacute, degenerative process that often results in debilitating pain located in the heel and bottom of the foot. RT002 is entering Phase 2 clinical trials for this condition.
A skin disorder characterized by abnormally increased sweating in excess of that required for thermoregulation. RT002 in the pre-clinical stage for this condition.
On May 27, 2003 Revance Therapeutics completed their series A funding round with $1.8 million in funding from undisclosed investors.
On April 27, 2004 Revance Therapeutics completed their series B funding round with $13 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, and Technology Partners.
On December 12, 2007 Revance Therapeutics completed their series C funding round with $43.5 million in funding from Medicis Pharmaceutical (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, and Essex Woodlands Health Ventures.
On January 4, 2010 Revance Therapeutics completed their series D funding round with $35 million in funding from Essex Woodlands Health Ventures (lead investor), Vivo Capital, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link, and EDBI.
On April 2, 2013 Revance Therapeutics completed their series E funding round with $33 million in funding from NovaQuest, Essex Woodlands Health Ventures, and Delphi Ventures.
